Sherborn, MA – According to filings with the U.S. Securities and Exchange Commission, CXL Ophthalmics is raising $50,298,762.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Michael Webb played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About CXL Ophthalmics
CXL Ophthalmics (CXLO) is developing innovative treatments for corneal diseases with the goal of saving and improving vision for millions of patients around the world. EpiSmart, its transformative cross-linking system targeting keratoconus, a common type of corneal ectasia, is designed to be minimally invasive with reduced discomfort and a significantly reduced recovery time versus current standards of care. CXLOs elegant approach will elevate the standard of care by enabling the treatment of both eyes simultaneously and eliminating the need for further deterioration. With a true Epi-On approach that does not disrupt the epithelium, CXLO is striving to deliver safer and more accessible vision-preserving care to millions of patients globally.

To learn more about CXL Ophthalmics, visit http://www.cxlophthalmics.com/

Contact:
Michael Webb, President and Chief Executive Officer
339-234-6020
https://www.linkedin.com/in/mike-webb-b347181/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved